| Literature DB >> 20547310 |
Silvia Tremosini1, María Reig, Carlos Rodríguez de Lope, Alejandro Forner, Jordi Bruix.
Abstract
In recent years, the wide implementation of surveillance programs has led to diagnose HCC at earlier stages, when curative options can be applied. In order to obtain the best results, treatment indication should take into account the estimation of baseline life expectancy. Patients at an early stage are those with single HCC or up to three nodules <3 cm with preserved liver function (Child-Pugh A-B) and no cancer related symptoms. These patients should be evaluated for any of the therapies that can offer complete responses with potential long-term cure, as reflected by a 5 years survival superior to 50-70%. These include surgical resection, liver transplantation and ablation. We briefly reviewed therapeutic management for early HCC, taking into account that any recommendation should be delivered in the clinical setting and based on an individualised evaluation of each patient. Copyright 2010 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd.. All rights reserved.Entities:
Mesh:
Year: 2010 PMID: 20547310 DOI: 10.1016/S1590-8658(10)60512-9
Source DB: PubMed Journal: Dig Liver Dis ISSN: 1590-8658 Impact factor: 4.088